These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36482388)

  • 1. Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Hafiz A; Alalawi M; Badreldin HA; Altebainawi AF; Vishwakarma R; Alissa A; Alghamdi A; Alenazi AA; Al Enazi H; Alanazi S; Alhammad A; Alghamdi J; AlFaifi M; Al Sehli FA; Aldossari MA; Alhubaishi AA; Al-Ali AY; Al-Dorzi HM
    Thromb J; 2022 Dec; 20(1):74. PubMed ID: 36482388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study.
    Aljuhani O; Al Sulaiman K; Hafiz A; Eljaaly K; Alharbi A; Algarni R; Al Homaid S; Kahtani K; Alsulaiman T; Vishwakarma R; Al Ghamdi G; Alalawi M; Korayem GB
    Saudi Pharm J; 2022 Apr; 30(4):398-406. PubMed ID: 35136364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
    Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
    J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis.
    Samuel S; Li W; Dunn K; Cortes J; Nguyen T; Moussa D; Kumar A; Dao T; Beeson J; Choi HA; McCullough LD
    J Thromb Thrombolysis; 2023 May; 55(4):617-625. PubMed ID: 37029256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients.
    Volteas P; Drakos P; Alkadaa LN; Cleri NA; Asencio AA; Oganov A; Giannopoulos S; Saadon JR; Mikell CB; Rubano JA; Labropoulos N; Tassiopoulos AK; Mofakham S; Bannazadeh M
    J Vasc Surg Venous Lymphat Disord; 2022 Sep; 10(5):1128-1136. PubMed ID: 35716998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence.
    AlLehaibi LH; Alomar M; Almulhim A; Al-Makki S; Alrwaili NR; Al-Bassam S; Alsultan S; Al Saeed J; Alsheef M; Abraham I; Alamer A
    Ann Pharmacother; 2023 Apr; 57(4):361-374. PubMed ID: 35942505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival implications vs. complications: unraveling the impact of vitamin D adjunctive use in critically ill patients with COVID-19-A multicenter cohort study.
    Al Sulaiman K; Korayem GB; Aljuhani O; Altebainawi AF; Shawaqfeh MS; Alarfaj SJ; Alharbi RA; Ageeli MM; Alissa A; Vishwakarma R; Ibrahim A; Alenazi AA; Alghnam S; Alshehri N; Alshammari MM; Alhubaishi A; Aldhaeefi M; Alamri FF; Syed Y; Khan R; Alalawi M; Alanazi KA; Alresayes FS; Albarqi KJ; Al Ghamdi G
    Front Med (Lausanne); 2023; 10():1237903. PubMed ID: 37692775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
    DeBiase C; Giuliano CA; Doshi M; Ganoff M; Alexander Paxton R
    Pharmacotherapy; 2021 May; 41(5):424-429. PubMed ID: 33641194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When antivirals backfire: An evaluation of favipiravir's clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Altebainawi AF; AlFaifi M; Nahari M; Almagthali A; Thabit AK; Alhajaji R; Alharbi R; Kahtani K; Alenazi AA; Alharbi A; Alghwainm MM; Alotaibi SM; Alghamdi YS; Alotaibi S; Alonazi SH; Almutairi JM; Vishwakarma R
    J Infect Public Health; 2023 Sep; 16(9):1492-1499. PubMed ID: 37355406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes.
    Al-Dorzi HM; Alqirnas MQ; Hegazy MM; Alghamdi AS; Alotaibi MT; Albogami MT; Alhafi MM; Alwadani S; Elsharkawi A; Arabi YM
    J Crit Care Med (Targu Mures); 2022 Oct; 8(4):249-258. PubMed ID: 36474613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.
    Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Badreldin HA; Alsalloum MA; Eljaaly K; Alharbi A; Aljehani R; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Al Aamer K; Al Enazi H; Almusallam M; Alshehri A; Bukhari R; Alasmari G; AlQahtani MM; Al Shammari S; Alsulaymi HO; Al Sulaiman K
    J Intensive Care Med; 2023 Jun; 38(6):534-543. PubMed ID: 36683420
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity.
    Amin A; Kartashov A; Ngai W; Steele K; Rosenthal N
    Front Cardiovasc Med; 2023; 10():1163684. PubMed ID: 37396589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure.
    Amin AN; Kartashov A; Ngai W; Steele K; Rosenthal N
    J Health Econ Outcomes Res; 2024; 11(1):44-56. PubMed ID: 38390025
    [No Abstract]   [Full Text] [Related]  

  • 15. Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study.
    Al Harbi S; Kensara R; Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Vishwakarma R; Alenazi AM; Almutairi A; Alshaya O; Alraddadi S; Al Sulaiman T; Aldakkan L; Mahboob R; Alaamer K; Alissa A; Hafiz A; Aldhayyan N; Althewaibi S; Alenezi F; Alkhotani NY; Alghamdi SA; Alenazi AA; Al Sulaiman K
    Clin Appl Thromb Hemost; 2022; 28():10760296221103864. PubMed ID: 35658686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxycycline's Potential Role in Reducing Thrombosis and Mortality in Critically Ill Patients With COVID-19: A Multicenter Cohort Study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Alnajjar LI; Altebainawi AF; AlFaifi M; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Alsowaida YS; Alsohimi S; Almagthali A; Alay SM; Altaher N; Alamri MG; Alangari D; Alzahrani A; Abdul Razack HI; Alhamoud J; Alshaya A; Gramish J; Al Aamer K; Alsaeedi AS; Alghamdi G
    Clin Appl Thromb Hemost; 2023; 29():10760296231177017. PubMed ID: 37322869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Hemodialysis Patients.
    Green MS; Tellor KB; Buckallew AR
    Hosp Pharm; 2017 Oct; 52(9):623-627. PubMed ID: 29276299
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
    ; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
    JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study.
    Al Harthi AF; Aljuhani O; Korayem GB; Altebainawi AF; Alenezi RS; Al Harbi S; Gramish J; Kensara R; Hafidh A; Al Enazi H; Alawad A; Alotaibi R; Alshehri A; Alhuthaili O; Vishwakarma R; Bin Saleh K; Alsulaiman T; Alqahtani RA; Hussain S; Almazrou S; Al Sulaiman K
    J Intensive Care Med; 2022 Sep; 37(9):1238-1249. PubMed ID: 35450493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients.
    McGarry LJ; Stokes ME; Thompson D
    Thromb J; 2006 Sep; 4():17. PubMed ID: 17005045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.